epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
Apitegromab
apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
Atacicept
atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Bevespi Aerosphere

glycopyrrolate/ formoterol inhaled

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Adult Dosing .

Dosage forms:  MDI: 9 mcg/4.8 mcg per actuation

COPD, maintenance tx

[2 puffs inhaled bid]
Max: 36 mcg/19.2 mcg/day; search 'gold' for epocrates COPD GOLD decision tools

renal dosing

[see below]
renal impairment: not defined; Info: caution advised if CrCl <30
HD/PD: not defined, caution advised

hepatic dosing

[see below]
hepatic impairment: not defined, caution advised

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@2a9a683d
  • hypersensitivity to drug or ingredient
  • asthma use
  • COPD, acute deteriorating
  • bronchospasm, acute
  • caution: MAO inhibitor use within 14 days
  • caution: TCA use within 14 days
  • caution: electrolyte abnormalities
  • caution: long QT syndrome, congenital
  • caution: QT prolongation
  • caution: QT prolongation family history
  • caution: torsades de pointes history
  • caution: arrhythmia
  • caution: bradycardia
  • caution: MI, recent
  • caution: CHF
  • caution: cardiovascular disease
  • caution: patients unusually responsive to sympathomimetic amines
  • caution: diabetes mellitus
  • caution: seizure disorder
  • caution: hyperthyroidism
  • caution: labor and delivery
  • caution: glaucoma, angle-closure
  • caution: CrCl <30
  • caution: urinary retention risk
  • caution: prostatic hypertrophy
  • caution: bladder neck obstruction
  • caution: hepatic impairment

Drug Interactions .

Overview

formoterol inhaled

beta-2 agonist

Interaction Characteristics:
  • hypertensive effects
  • hypokalemia
  • prolongs QT interval (conditional)
  • tachycardia

glycopyrrolate inhaled

anticholinergic inhaled

Interaction Characteristics:
  • anticholinergic effects

Contraindicated

  • pimozide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pimozide
    2 interactions

    Contraindicated

    formoterol inhaled + pimozide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + pimozide

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • thioridazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    thioridazine
    2 interactions

    Contraindicated

    formoterol inhaled + thioridazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + thioridazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

Avoid/Use Alternative

  • aclidinium inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aclidinium inhaled
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + aclidinium inhaled

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • albuterol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    albuterol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + albuterol

    consider alternative if long-term use; otherwise, monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia (additive effects, duplicate therapy)

  • amantadine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amantadine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + amantadine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • arformoterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    arformoterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + arformoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • arsenic trioxide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + arsenic trioxide

    use alternative or monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • atropine ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    atropine ophthalmic
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + atropine ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + atropine ophthalmic

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bedaquiline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • botulinum toxin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    botulinum toxin
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + botulinum toxin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • carvedilol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    carvedilol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + carvedilol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • chlophedianol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlophedianol
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + chlophedianol

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • chlorcyclizine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlorcyclizine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + chlorcyclizine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clozapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clozapine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + clozapine

    use alternative: combo may incr. risk of severe constipation, paralytic ileus (including life-threatening), other anticholinergic adverse effects (additive effects)

  • cocaine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cocaine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + cocaine

    use alternative or monitor BP, HR, ECG: combo may incr. risk of severe vasoconstriction, HTN, tachycardia, arrhythmias (additive effects)

  • crizotinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + crizotinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • cyclopentolate ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cyclopentolate ophthalmic
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + cyclopentolate ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • darifenacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    darifenacin
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + darifenacin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • desipramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    desipramine
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + desipramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + desipramine

    monitor ECG, BP, HR during and x2wk after desipramine D/C: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dexbrompheniramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexbrompheniramine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + dexbrompheniramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dexchlorpheniramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexchlorpheniramine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + dexchlorpheniramine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • domperidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    domperidone
    2 interactions

    Avoid/Use Alternative

    formoterol inhaled + domperidone

    use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + domperidone

    caution advised: combo may decr. domperidone efficacy (antagonistic effects)

  • doxepin topical
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    doxepin topical
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + doxepin topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dronabinol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dronabinol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + dronabinol

    avoid combo: combo may incr. risk of HTN, tachycardia (additive effects)

  • dronedarone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dronedarone
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + dronedarone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedra
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    epinephrine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + epinephrine

    use alternative or monitor BP, HR, potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epinephrine inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    epinephrine inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + epinephrine inhaled

    avoid combo: combo may incr. risk of HTN (including hypertensive crisis), tachycardia, other cardiovascular adverse effects (additive effects)

  • fesoterodine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fesoterodine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + fesoterodine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • fexinidazole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after formoterol D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fluphenazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fluphenazine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + fluphenazine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • formoterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    formoterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + formoterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • fosfomycin injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + fosfomycin injection

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • furosemide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    furosemide
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + furosemide

    use alternative or monitor BP, potassium: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia, ECG changes (antagonistic effects; additive effects)

  • glucagon
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    glucagon
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + glucagon

    avoid combo if glucagon used as radiologic diagnostic aid: combo may incr. risk of severe constipation, paralytic ileus, other GI adverse effects (additive effects)

  • glycopyrrolate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    glycopyrrolate
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + glycopyrrolate

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + glycopyrrolate

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • glycopyrronium topical
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    glycopyrronium topical
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + glycopyrronium topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • hydroxychloroquine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + hydroxychloroquine

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ipratropium nasal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ipratropium nasal
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + ipratropium nasal

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • labetalol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    labetalol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + labetalol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • landiolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    landiolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + landiolol

    use alternative or monitor HR, BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • lefamulin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lonafarnib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lonafarnib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + lonafarnib

    use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • midodrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    midodrine
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + midodrine

    use alternative or monitor BP: combo may incr. risk of HTN (additive effects)

  • mobocertinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • molindone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    molindone
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + molindone

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • nadolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nadolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + nadolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • nebivolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nebivolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + nebivolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • olanzapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    olanzapine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + olanzapine

    avoid combo: combo may incr. risk of life-threatening anticholinergic adverse effects, including constipation, paralytic ileus, hyperthermia (additive effects)

  • olodaterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    olodaterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + olodaterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse events or fatalities (additive effects, duplicate long-acting beta 2 agonist tx)

  • oxybutynin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxybutynin
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + oxybutynin

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • phenelzine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenelzine
    2 interactions

    Avoid/Use Alternative

    formoterol inhaled + phenelzine

    consider alternative or monitor BP, HR during and x2wk after phenelzine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + phenelzine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • pindolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pindolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + pindolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • pramlintide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pramlintide
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + pramlintide

    consider alternative: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • propranolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    propranolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + propranolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • quinidine (antiarrhythmic)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quinidine (antiarrhythmic)
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + quinidine (antiarrhythmic)

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + quinidine (antiarrhythmic)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quinidine (CYP2D6 inhibitor)
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + quinidine (CYP2D6 inhibitor)

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quizartinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • revefenacin inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    revefenacin inhaled
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + revefenacin inhaled

    avoid combo: combo may incr. anticholinergic adverse effects (additive effects)

  • rivastigmine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rivastigmine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + rivastigmine

    use alternative: combo may decrease efficacy of both drugs (antagonistic effects)

  • salmeterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    salmeterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + salmeterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • sofpironium topical
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sofpironium topical
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + sofpironium topical

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • sotalol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • thiothixene
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    thiothixene
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + thiothixene

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • timolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    timolol
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + timolol

    use alternative or monitor BP, COPD sx; consider cardioselective beta blocker: combo may decr. efficacy of both drugs (antagonistic effects)

  • tolterodine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tolterodine
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + tolterodine

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • toremifene
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trihexyphenidyl
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trihexyphenidyl
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + trihexyphenidyl

    avoid combo: combo may incr. risk of hyperthermia, anticholinergic adverse effects (additive effects)

  • tropicamide ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tropicamide ophthalmic
    1 interaction

    Avoid/Use Alternative

    glycopyrrolate inhaled + tropicamide ophthalmic

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • trospium
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trospium
    2 interactions

    Avoid/Use Alternative

    glycopyrrolate inhaled + trospium

    avoid combo: combo may incr. risk of anticholinergic adverse effects (additive effects)

    Monitor/Modify Tx

    formoterol inhaled + trospium

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • vandetanib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + vandetanib

    use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • vilanterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vilanterol inhaled
    1 interaction

    Avoid/Use Alternative

    formoterol inhaled + vilanterol inhaled

    avoid combo: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • ziprasidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ziprasidone
    2 interactions

    Avoid/Use Alternative

    formoterol inhaled + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + ziprasidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

Monitor/Modify Tx

  • abiraterone acetate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + abiraterone acetate

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • acebutolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    acebutolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + acebutolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • acetazolamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • adagrasib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    adagrasib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + adagrasib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • albuterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + albuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • aliskiren
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aliskiren
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aliskiren

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • almotriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    almotriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + almotriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • aloe
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amiloride

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • aminophylline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aminophylline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aminophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • amiodarone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amiodarone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amitriptyline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amitriptyline
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + amitriptyline

    monitor BP, HR during and x2wk after amitriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + amitriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • amlodipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amlodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amlodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • amoxapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amoxapine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + amoxapine

    monitor BP, HR during and x2wk after amoxapine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + amoxapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • amphetamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • amphotericin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • anagrelide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + anagrelide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • angiotensin II
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    angiotensin II
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + angiotensin II

    monitor BP: combo may incr. risk of HTN (additive effects)

  • apalutamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    apalutamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + apalutamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apomorphine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + apomorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • aprocitentan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aprocitentan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + aprocitentan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • armodafinil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    armodafinil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + armodafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • artemether/lumefantrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + artemether/ lumefantrine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asciminib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    asciminib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + asciminib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • asenapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    asenapine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + asenapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + asenapine

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • asparaginase
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atenolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    atenolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atenolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • atogepant
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    atogepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • atomoxetine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    atomoxetine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + atomoxetine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • atropine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    atropine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + atropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + atropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • axitinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    axitinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + axitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • azilsartan medoxomil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    azilsartan medoxomil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + azilsartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • azithromycin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    azithromycin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + azithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • benazepril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    benazepril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + benazepril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • benzphetamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    benzphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + benzphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • benztropine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    benztropine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + benztropine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + benztropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • betamethasone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + betamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • betaxolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    betaxolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + betaxolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • bevacizumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bevacizumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bevacizumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • bismuth subsalicylate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bismuth subsalicylate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bismuth subsalicylate

    monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

  • bisoprolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bisoprolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bisoprolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • brigatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    brigatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + brigatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • budesonide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + budesonide

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • bumetanide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bumetanide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • bupropion
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bupropion
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + bupropion

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • cabozantinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cabozantinib

    monitor BP, ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • caffeine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    caffeine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + caffeine

    monitor BP, HR; avoid excessive caffeine intake: combo may incr. risk of HTN, tachycardia (additive effects)

  • caffeine citrate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    caffeine citrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + caffeine citrate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • candesartan cilexetil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    candesartan cilexetil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + candesartan cilexetil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • cannabis
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cannabis
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cannabis

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • captopril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    captopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + captopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • carfilzomib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + carfilzomib

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • celecoxib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    celecoxib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + celecoxib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ceritinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ceritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cetuximab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chloroquine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chloroquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chlorothiazide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • chlorthalidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + chlorthalidone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • cisplatin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cisplatin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • citalopram
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + citalopram

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clarithromycin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clarithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clevidipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clevidipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clevidipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • clofazimine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clofazimine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clomipramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clomipramine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + clomipramine

    monitor BP, HR during and x2wk after clomipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    glycopyrrolate inhaled + clomipramine

    consider decr. dose of one or both drugs: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clonidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clonidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + clonidine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • copanlisib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    copanlisib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + copanlisib

    monitor BP: combo may incr. risk of HTN (additive effects, copanlisib may cause infusion-related HTN)

  • corticotropin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + corticotropin

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • cortisone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • cyclosporine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cyclosporine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + cyclosporine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • danazol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    danazol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + danazol

    monitor BP: combo may incr. risk of HTN (additive effects)

  • darbepoetin alfa
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    darbepoetin alfa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + darbepoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • decitabine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

  • deflazacort
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + deflazacort

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • degarelix
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    degarelix
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + degarelix

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desmopressin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    desmopressin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desmopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • desvenlafaxine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    desvenlafaxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + desvenlafaxine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • dexamethasone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexamethasone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • dexmedetomidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmedetomidine

    monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmedetomidine injection

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmethylphenidate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dexmethylphenidate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dexmethylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dextroamphetamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dextroamphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dextroamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dichlorphenamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • diclofenac
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diclofenac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diclofenac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • diclofenac topical
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diclofenac topical
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diclofenac topical

    monitor BP: combo may incr. risk of HTN (additive effects)

  • dicyclomine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dicyclomine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + dicyclomine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + dicyclomine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • diethylpropion
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diethylpropion
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diethylpropion

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • diflunisal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diflunisal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diflunisal

    monitor BP: combo may incr. risk of HTN (additive effects)

  • digoxin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    digoxin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + digoxin

    monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

  • dihydroergotamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dihydroergotamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dihydroergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • diltiazem
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diltiazem
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + diltiazem

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • dinutuximab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • disopyramide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    disopyramide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + disopyramide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + disopyramide

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • dobutamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dobutamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dobutamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dofetilide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dofetilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • donepezil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    donepezil
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + donepezil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + donepezil

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • dopamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dopamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dopamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • dordaviprone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dordaviprone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + dordaviprone

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • doxapram
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    doxapram
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + doxapram

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • doxazosin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    doxazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + doxazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • doxepin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    doxepin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + doxepin

    monitor BP, HR during and x2wk after doxepin D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + doxepin

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • droperidol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + droperidol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droxidopa
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    droxidopa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + droxidopa

    monitor BP: combo may incr. risk of supine HTN (additive effects)

  • eletriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    eletriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eletriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • emapalumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    emapalumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • enalapril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    enalapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + enalapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • enalaprilat
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    enalaprilat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + enalaprilat

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • encorafenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + encorafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ephedrine injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ephedrine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ephedrine injection

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • ephedrine oral
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ephedrine oral
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ephedrine oral

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • epirubicin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + epirubicin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • eplerenone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    eplerenone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eplerenone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • epoetin alfa
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    epoetin alfa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + epoetin alfa

    monitor BP: combo may incr. risk of HTN (additive effects)

  • eptinezumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    eptinezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eptinezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • erenumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    erenumab
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + erenumab

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    glycopyrrolate inhaled + erenumab

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • ergotamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ergotamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ergotamine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • eribulin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    eribulin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + eribulin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • erythromycin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    erythromycin
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + erythromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + erythromycin

    caution advised: combo may decr. erythromycin efficacy when used for GI promotility (antagonistic effects)

  • esketamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    esketamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + esketamine

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • esmolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    esmolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + esmolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • estetrol (contraceptive)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    estetrol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + estetrol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • estradiol (contraceptive)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ethacrynic acid
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethacrynic acid

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • ethanol (alcoholic beverage)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ethanol (alcoholic beverage)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethanol (alcoholic beverage)

    monitor BP: combo may incr. risk of HTN (chronic alcohol use) (additive effects)

  • ethinyl estradiol (contraceptive)
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ethinyl estradiol (contraceptive)
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ethinyl estradiol (contraceptive)

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etodolac
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    etodolac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + etodolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • etrasimod
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    etrasimod
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + etrasimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • felodipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    felodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + felodipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenfluramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fenfluramine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenfluramine

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • fenoldopam
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fenoldopam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenoldopam

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fenoprofen
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fenoprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fenoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fingolimod
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fingolimod
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fingolimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • flecainide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + flecainide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fludrocortisone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fludrocortisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • fluorouracil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fluorouracil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flurbiprofen
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    flurbiprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + flurbiprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • foscarnet
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + foscarnet

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • fosinopril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fosinopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fosinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • fostamatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fostamatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fremanezumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fremanezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fremanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • frovatriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    frovatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + frovatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • fruquintinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fruquintinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + fruquintinib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • galcanezumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    galcanezumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + galcanezumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • gilteritinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + gilteritinib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • glasdegib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + glasdegib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • goserelin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + goserelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • guanfacine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    guanfacine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + guanfacine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • haloperidol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + haloperidol

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    histrelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + histrelin

    consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hoodia
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hoodia
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hoodia

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • hydralazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydralazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydralazine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • hydrochlorothiazide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydrochlorothiazide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • hydrocortisone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydrocortisone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • hydroxocobalamin IV
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydroxocobalamin IV
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + hydroxocobalamin IV

    monitor BP: combo may incr. risk of HTN (additive effects)

  • hydroxyzine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydroxyzine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + hydroxyzine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + hydroxyzine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • hyoscyamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hyoscyamine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + hyoscyamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + hyoscyamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • ibrutinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ibrutinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ibrutinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibuprofen
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ibuprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ibuprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ibutilide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ibutilide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ibutilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • imipramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    imipramine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + imipramine

    monitor BP, HR during and x2wk after imipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + imipramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • indapamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + indapamide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • indomethacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    indomethacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + indomethacin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • inotuzumab ozogamicin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    inotuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + inotuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • insulin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • irbesartan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    irbesartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + irbesartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • isocarboxazid
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    isocarboxazid
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + isocarboxazid

    monitor BP, HR during and x2wk after isocarboxazid D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + isocarboxazid

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • isoflurane
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoproterenol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isoproterenol

    monitor potassium, HR: combo may incr. risk of hypokalemia, tachycardia (additive effects)

  • isradipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    isradipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + isradipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ivosidenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ivosidenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ketamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ketamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other sympathomimetic adverse effects (additive effects)

  • ketoprofen
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ketoprofen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketoprofen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ketorolac
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ketorolac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ketorolac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lanreotide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lanreotide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lanreotide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leflunomide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + leflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • lenalidomide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • lenvatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lenvatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lenvatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • leuprolide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + leuprolide

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levalbuterol inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levalbuterol inhaled

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • levofloxacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levoketoconazole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levoketoconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levomilnacipran
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levomilnacipran
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levomilnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • levothyroxine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levothyroxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + levothyroxine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • licorice
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + licorice

    monitor BP, potassium w/ large amounts of licorice: combo may incr. risk of HTN, hypokalemia (additive effects)

  • lifileucel
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lifileucel
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lifileucel

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • linezolid
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + linezolid

    monitor BP, HR during and x2wk after linezolid D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • liothyronine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    liothyronine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + liothyronine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • liraglutide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    liraglutide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + liraglutide

    monitor HR: combo may incr. risk of tachycardia (additive effects)

  • lisdexamfetamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lisdexamfetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lisdexamfetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • lisinopril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lisinopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lisinopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lofexidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lofexidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lofexidine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lorlatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lorlatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lorlatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • losartan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    losartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + losartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • lumacaftor/ivacaftor
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lumacaftor/ ivacaftor
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + lumacaftor/ ivacaftor

    monitor BP: combo may incr. risk of HTN (additive effects)

  • luspatercept
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    luspatercept
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + luspatercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • macimorelin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    macimorelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + macimorelin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium citrate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium salicylate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    magnesium salicylate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + magnesium salicylate

    monitor BP w/ high-dose magnesium salicylate: combo may incr. risk of HTN (additive effects)

  • mannitol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mannitol

    monitor potassium, cardiac fxn: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • meclofenamate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    meclofenamate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + meclofenamate

    monitor BP: combo may incr. risk of HTN (additive effects)

  • mefenamic acid
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mefenamic acid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mefenamic acid

    monitor BP: combo may incr. risk of HTN (additive effects)

  • meloxicam
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    meloxicam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + meloxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methacholine inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methacholine inhaled
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methacholine inhaled

    hold ultra-LABA formoterol x48h before diagnostic test: combo may interfere with test results (antagonistic effects)

  • methadone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methadone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + methadone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + methadone

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • methamphetamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methamphetamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methamphetamine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methazolamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methoxy polyethylene glycol-epoetin beta
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methoxy polyethylene glycol-epoetin beta
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methoxy polyethylene glycol-epoetin beta

    monitor BP: combo may incr. risk of HTN (additive effects)

  • methscopolamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methscopolamine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + methscopolamine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + methscopolamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • methyldopa
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methyldopa
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methyldopa

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • methylergonovine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methylergonovine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methylergonovine

    monitor BP: combo may incr. risk of severe HTN, vasospasm, ischemia (additive effects)

  • methylphenidate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methylphenidate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methylphenidate

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • methylprednisolone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methylprednisolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • methyltestosterone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    methyltestosterone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + methyltestosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • metoclopramide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    metoclopramide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + metoclopramide

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    glycopyrrolate inhaled + metoclopramide

    caution advised: combo may decr. metoclopramide efficacy (antagonistic effects; absorption of oral metoclopramide affected by delayed gastric emptying)

  • metolazone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + metolazone

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • metoprolol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    metoprolol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + metoprolol

    monitor BP, COPD sx: combo may decr. efficacy of both drugs (antagonistic effects)

  • mifepristone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mifepristone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + mifepristone

    monitor potassium if daily mifepristone use: combo may incr. risk of hypokalemia (additive effects)

  • milnacipran
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    milnacipran
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + milnacipran

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • minoxidil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    minoxidil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + minoxidil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • mirabegron
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mirabegron
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + mirabegron

    monitor BP: combo may incr. risk of HTN (additive effects)

    Caution Advised

    glycopyrrolate inhaled + mirabegron

    caution advised: combo may incr. risk of urinary retention (additive effects)

  • modafinil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    modafinil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + modafinil

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • moexipril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    moexipril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + moexipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • motixafortide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • moxifloxacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + moxifloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • nabumetone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nabumetone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nabumetone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naproxen
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    naproxen
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naproxen

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naratriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    naratriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naratriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • naxitamab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    naxitamab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + naxitamab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • necitumumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • nicardipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nicardipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nicardipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nicotine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nicotine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nicotine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • nifedipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nifedipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nifedipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • nilotinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nilotinib

    monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • nimodipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nimodipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nimodipine

    monitor BP: combo may decr. nimodipine efficacy (antagonistic effects)

  • niraparib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    niraparib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + niraparib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • nisoldipine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nisoldipine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + nisoldipine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • norepinephrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    norepinephrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + norepinephrine

    monitor BP, HR: combo may incr. risk of HTN, cardiovascular adverse effects (additive effects)

  • nortriptyline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nortriptyline
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + nortriptyline

    monitor BP, HR during and x2wk after nortriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + nortriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • obinutuzumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    obinutuzumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + obinutuzumab

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • oliceridine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oliceridine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + oliceridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + oliceridine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, other anticholinergic adverse effects (additive effects)

  • olmesartan medoxomil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    olmesartan medoxomil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + olmesartan medoxomil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ondansetron
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ondansetron
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ondansetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • orphenadrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    orphenadrine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + orphenadrine

    monitor HR: combo may incr. risk of tachycardia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + orphenadrine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • osilodrostat
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + osilodrostat

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • osimertinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    osimertinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + osimertinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxaprozin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxaprozin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxaprozin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • oxymetazoline nasal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxymetazoline nasal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxymetazoline nasal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • oxytocin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxytocin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + oxytocin

    monitor BP: combo may incr. risk of HTN, including life-threatening (additive effects)

  • ozanimod
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ozanimod
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ozanimod

    monitor BP, HR during and x2wk after ozanimod D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • pacritinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pacritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • paliperidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    paliperidone
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + paliperidone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + paliperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • palonosetron
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    palonosetron
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + palonosetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pamidronate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pasireotide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pasireotide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pazopanib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pazopanib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pazopanib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • pentamidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pentamidine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pentamidine

    monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • perindopril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    perindopril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + perindopril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • pexidartinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pexidartinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pexidartinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • phendimetrazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phendimetrazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phendimetrazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenoxybenzamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenoxybenzamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenoxybenzamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phentermine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phentermine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phentermine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phentolamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phentolamine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phentolamine

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • phenylephrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenylephrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenylephrine injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenylephrine injection
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine injection

    monitor BP, HR: combo may incr. risk of HTN, cardiovascular adverse effects (additive effects)

  • phenylephrine nasal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenylephrine nasal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine nasal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • phenylephrine ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenylephrine ophthalmic
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine ophthalmic

    monitor BP, HR; risk may be lower w/ phenylephrine ophthalmic 2.5%: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • phenylephrine rectal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    phenylephrine rectal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + phenylephrine rectal

    monitor BP, HR: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • piroxicam
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    piroxicam
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + piroxicam

    monitor BP: combo may incr. risk of HTN (additive effects)

  • polyethylene glycol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • ponatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ponatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ponatinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ponesimod
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ponesimod
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ponesimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • posaconazole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + posaconazole

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • pralsetinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pralsetinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pralsetinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • prazosin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    prazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + prazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • prednisolone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + prednisolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • prednisone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + prednisone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • procainamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + procainamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • procarbazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    procarbazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + procarbazine

    monitor BP, HR during and x2wk after procarbazine D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • propafenone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + propafenone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • protriptyline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    protriptyline
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + protriptyline

    monitor BP, HR during and x2wk after protriptyline D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + protriptyline

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pseudoephedrine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pseudoephedrine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + pseudoephedrine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • quetiapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quetiapine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + quetiapine

    monitor BP, especially in pts <18 yo: combo may incr. risk of HTN (additive effects)

    Caution Advised

    glycopyrrolate inhaled + quetiapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • quinapril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quinapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • quinine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + quinine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ramipril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ramipril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ramipril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • ramucirumab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ramucirumab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ramucirumab

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rasagiline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rasagiline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rasagiline

    monitor BP, HR during and x2wk after rasagiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • regorafenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    regorafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + regorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • revumenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + revumenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribociclib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ribociclib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rimegepant
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rimegepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rimegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ripretinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ripretinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ripretinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rizatriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rizatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rizatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • romidepsin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    romidepsin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + romidepsin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ropinirole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ropinirole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ropinirole

    monitor BP: combo may incr. risk of HTN (additive effects)

  • rotigotine transdermal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rotigotine transdermal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rotigotine transdermal

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • rucaparib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + rucaparib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sacituzumab govitecan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sacituzumab govitecan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sacituzumab govitecan

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • safinamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    safinamide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + safinamide

    monitor BP, HR during and x2wk after safinamide D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • salsalate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    salsalate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + salsalate

    monitor BP w/ high-dose salsalate: combo may incr. risk of HTN (additive effects)

  • selegiline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    selegiline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selegiline

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN, other cardiovascular adverse effects (additive effects)

  • selegiline transdermal
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    selegiline transdermal
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selegiline transdermal

    monitor BP, HR during and x2wk after selegiline D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

  • selinexor
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    selinexor
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • selpercatinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + selpercatinib

    monitor BP, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, HTN (additive effects)

  • sevoflurane
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sevoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • siponimod
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    siponimod
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + siponimod

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sirolimus albumin-bound
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sirolimus albumin-bound

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium benzoate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • solriamfetol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    solriamfetol
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + solriamfetol

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • sorafenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sorafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sorafenib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • spironolactone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    spironolactone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + spironolactone

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • sulfate bowel prep
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sulindac
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sulindac
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sulindac

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sumatriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sumatriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sumatriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • sunitinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sunitinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + sunitinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tacrolimus
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tacrolimus
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tacrolimus

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tafasitamab
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tafasitamab
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • tagraxofusp
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tagraxofusp

    monitor BP: combo may incr. risk of HTN (additive effects)

  • taletrectinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + taletrectinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telavancin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + telavancin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telmisartan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    telmisartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + telmisartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terazosin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    terazosin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + terazosin

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • terbutaline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + terbutaline

    monitor potassium, BP, HR: combo may incr. risk of hypokalemia, HTN, tachycardia, other cardiovascular adverse effects (additive effects, duplicate therapy)

  • teriflunomide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + teriflunomide

    monitor BP: combo may incr. risk of HTN (additive effects)

  • testosterone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    testosterone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + testosterone

    monitor BP: combo may incr. risk of HTN (additive effects)

  • tetrabenazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • theophylline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    theophylline
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + theophylline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • thyroid
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    thyroid
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + thyroid

    monitor BP, HR: combo may incr. risk of HTN, tachycardia (additive effects)

  • tivozanib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tivozanib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tivozanib

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • tolmetin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tolmetin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + tolmetin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • topiramate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    topiramate
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + topiramate

    caution advised, especially in Peds pts: combo may incr. risk of hyperthermia (additive effects)

  • torsemide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + torsemide

    monitor potassium, BP: combo may incr. risk of hypokalemia, ECG changes; may decr. antihypertensive agent efficacy (additive effects; antagonistic effects)

  • tramadol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tramadol
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + tramadol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

    Caution Advised

    glycopyrrolate inhaled + tramadol

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • trametinib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trametinib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trametinib

    monitor BP: combo may incr. risk of HTN (additive effects)

  • trandolapril
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trandolapril
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trandolapril

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • tranylcypromine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tranylcypromine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + tranylcypromine

    monitor BP, HR during and x2wk after tranylcypromine D/C: combo may incr. risk of HTN (including hypertensive crisis), other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + tranylcypromine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • triamcinolone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triamcinolone

    monitor potassium, BP: combo may incr. risk of hypokalemia, HTN (additive effects)

  • triamterene
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triamterene

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • triclabendazole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triclabendazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trifluridine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + trifluridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trimipramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trimipramine
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + trimipramine

    monitor BP, HR during and x2wk after trimipramine D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

    Caution Advised

    glycopyrrolate inhaled + trimipramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • triptorelin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + triptorelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • ubrogepant
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ubrogepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ubrogepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vadadustat
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vadadustat
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vadadustat

    monitor BP: combo may incr. risk of HTN, including hypertensive crisis (additive effects)

  • valsartan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    valsartan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + valsartan

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • vamorolone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vamorolone

    monitor BP, potassium: combo may incr. risk of HTN, hypokalemia (additive effects)

  • vasopressin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vasopressin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vasopressin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • vemurafenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + vemurafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venlafaxine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + venlafaxine

    monitor BP: combo may incr. risk of HTN (additive effects)

  • verapamil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    verapamil
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + verapamil

    monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects)

  • viloxazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    viloxazine
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + viloxazine

    monitor BP, HR: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • voclosporin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    voclosporin
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + voclosporin

    monitor BP: combo may incr. risk of HTN (additive effects)

  • yohimbe
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    yohimbe
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + yohimbe

    monitor BP, HR during and x2wk after yohimbe D/C: combo may incr. risk of HTN, tachycardia, other cardiovascular adverse effects (additive effects)

  • zavegepant
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    zavegepant
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + zavegepant

    monitor BP: combo may incr. risk of HTN (additive effects)

  • ziftomenib
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ziftomenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziv-aflibercept
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ziv-aflibercept
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + ziv-aflibercept

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zolmitriptan
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    zolmitriptan
    1 interaction

    Monitor/Modify Tx

    formoterol inhaled + zolmitriptan

    monitor BP: combo may incr. risk of HTN (additive effects)

  • zonisamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    zonisamide
    2 interactions

    Monitor/Modify Tx

    formoterol inhaled + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

    Caution Advised

    glycopyrrolate inhaled + zonisamide

    caution advised, especially in Peds pts: combo may incr. risk of hyperthermia (additive effects)

Caution Advised

  • aceclidine ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aceclidine ophthalmic
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + aceclidine ophthalmic

    caution advised: combo may decr. aceclidine efficacy (antagonistic effects)

  • alfentanil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    alfentanil
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + alfentanil

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • alosetron
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    alosetron
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + alosetron

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • aripiprazole bimonthly injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aripiprazole bimonthly injection
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + aripiprazole bimonthly injection

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole lauroxil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aripiprazole lauroxil
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + aripiprazole lauroxil

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole monthly injection
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aripiprazole monthly injection
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + aripiprazole monthly injection

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • aripiprazole oral
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    aripiprazole oral
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + aripiprazole oral

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • belladonna alkaloids
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    belladonna alkaloids
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + belladonna alkaloids

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • bethanechol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    bethanechol
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + bethanechol

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • brexpiprazole
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    brexpiprazole
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + brexpiprazole

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • brompheniramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    brompheniramine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + brompheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • buprenorphine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    buprenorphine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + buprenorphine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • butorphanol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    butorphanol
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + butorphanol

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • carbinoxamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    carbinoxamine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + carbinoxamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • cariprazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cariprazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + cariprazine

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • cevimeline
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cevimeline
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + cevimeline

    caution advised: combo may decrease efficacy of both drugs (antagonistic effects)

  • chlorpheniramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlorpheniramine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + chlorpheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • chlorpromazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    chlorpromazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + chlorpromazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clemastine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clemastine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + clemastine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • clidinium
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    clidinium
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + clidinium

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • codeine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    codeine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + codeine

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • cyclobenzaprine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cyclobenzaprine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + cyclobenzaprine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • cyproheptadine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    cyproheptadine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + cyproheptadine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • difenoxin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    difenoxin
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + difenoxin

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • dihydrocodeine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dihydrocodeine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + dihydrocodeine

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • dimenhydrinate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    dimenhydrinate
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + dimenhydrinate

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • diphenhydramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diphenhydramine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + diphenhydramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • diphenoxylate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    diphenoxylate
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + diphenoxylate

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • doxylamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    doxylamine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + doxylamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • fentanyl
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    fentanyl
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + fentanyl

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • flavoxate
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    flavoxate
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + flavoxate

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • galantamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    galantamine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + galantamine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • gepotidacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    gepotidacin
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + gepotidacin

    caution advised: combo may decr. glycopyrrolate efficacy (antagonistic effects, gepotidacin reversibly inhibits acetylcholinesterase)

  • homatropine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    homatropine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + homatropine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • hydrocodone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydrocodone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + hydrocodone

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • hydromorphone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    hydromorphone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + hydromorphone

    caution advised: combo may incr. risk of severe constipation, paralytic ileus (additive effects)

  • iloperidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    iloperidone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + iloperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • ipratropium inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    ipratropium inhaled
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + ipratropium inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • levorphanol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    levorphanol
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + levorphanol

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • loperamide
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    loperamide
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + loperamide

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • loxapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    loxapine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + loxapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • lumateperone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lumateperone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + lumateperone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • lurasidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    lurasidone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + lurasidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • meclizine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    meclizine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + meclizine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • meperidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    meperidine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + meperidine

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • milsaperidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    milsaperidone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + milsaperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • mirtazapine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    mirtazapine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + mirtazapine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • morphine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    morphine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + morphine

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • nalbuphine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    nalbuphine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + nalbuphine

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • neostigmine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    neostigmine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + neostigmine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • oxycodone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxycodone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + oxycodone

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • oxymorphone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    oxymorphone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + oxymorphone

    caution advised: combo may incr. risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • pentazocine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pentazocine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pentazocine

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • perphenazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    perphenazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + perphenazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pheniramine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pheniramine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pheniramine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pilocarpine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pilocarpine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pilocarpine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • pilocarpine ophthalmic
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pilocarpine ophthalmic
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pilocarpine ophthalmic

    caution advised: combo may decr. pilocarpine efficacy (antagonistic effects)

  • prochlorperazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    prochlorperazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + prochlorperazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • promethazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    promethazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + promethazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • pyridostigmine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pyridostigmine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pyridostigmine

    caution advised: combo may decr. efficacy of both drugs (antagonistic effects)

  • pyrilamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    pyrilamine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + pyrilamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • remifentanil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    remifentanil
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + remifentanil

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • risperidone
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    risperidone
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + risperidone

    caution advised: combo may incr. risk of hyperthermia (additive effects)

  • scopolamine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    scopolamine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + scopolamine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • solifenacin
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    solifenacin
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + solifenacin

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • sufentanil
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    sufentanil
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + sufentanil

    caution advised: combo may incr. risk of severe constipation/paralytic ileus, other anticholinergic adverse effects (additive effects)

  • tapentadol
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tapentadol
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + tapentadol

    caution advised: combo may increase risk of severe constipation, paralytic ileus, urinary retention (additive effects)

  • tiotropium inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    tiotropium inhaled
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + tiotropium inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • trifluoperazine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    trifluoperazine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + trifluoperazine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • triprolidine
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    triprolidine
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + triprolidine

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • umeclidinium inhaled
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    umeclidinium inhaled
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + umeclidinium inhaled

    caution advised: combo may incr. risk of anticholinergic adverse effects (additive effects)

  • vibegron
  • Bevespi Aerosphere (glycopyrrolate/ formoterol inhaled)
    +
    vibegron
    1 interaction

    Caution Advised

    glycopyrrolate inhaled + vibegron

    caution advised: combo may incr. risk of urinary retention (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@43c874b5
  • hypersensitivity reaction
  • anaphylaxis
  • death, asthma-related (tx without concurrent inhaled corticosteroid)
  • bronchospasm, paradoxical
  • COPD exacerbation
  • glaucoma, acute angle-closure
  • HTN
  • angina
  • atrial fibrillation
  • arrhythmia
  • hypokalemia
  • hyperglycemia

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@4fe4371c
  • cough
  • UTI

Safety/Monitoring .

Monitoring Parameters
no routine tests recommended

Pregnancy/Lactation .

Pregnancy

Clinical Summary

glycopyrrolate inhaled: weigh risk/benefit during pregnancy; no human data available, though risk of fetal harm not expected based on limited human data with oral form; no known risk of teratogenicity based on animal data at 270x MRHD

formoterol inhaled: weigh risk/benefit during pregnancy, especially during labor and delivery; inadequate human data available; risk of fetal harm low, though possible risk of delayed ossification based on animal data at 50x MRHD; risk of interference with uterine contractility based on drug's mechanism of action

Lactation

Clinical Summary

glycopyrrolate inhaled: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients and drug properties; no human data available to assess effects on milk production

formoterol inhaled: may use while breastfeeding; no human data available, though risk of infant harm not expected based on minimal systemic absorption in breastfeeding patients; no human data available to assess effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@6141865f

Metabolism: for glycopyrrolate: unknown; CYP450: 2D6 substrate; for formoterol: liver extensively; CYP450: A26, 2C9/19, 2D6 substrate; UGT: 1A1, 1A8, 1A9, 2B7, 2B15 substrate; Info: minimal systemic absorption

Excretion: for glycopyrrolate: urine 85%, bile; Half-life: 11.8h; for formoterol: urine 62%, feces 24%; Half-life: 11.8h

Subclass: Beta-2 Agonists, Inhaled Long-Acting (LABAs) ; Muscarinic Antagonists, Inhaled Long-Acting (LAMAs)

Mechanism of Action
for glycopyrrolate: antagonizes acetylcholine receptors, producing bronchodilation; for formoterol: selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: AstraZeneca Pharmaceuticals LP

com.epocrates.rxweb.beans.DrugOtherInfoBean@69d56eb1

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

inhalation aerosol:

  • 9 mcg/4.8 mcg (1 inhaler, 10.7 g): $413.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information